Avalo Therapeutics (AVTX) Cash from Operations (2014 - 2026)
Avalo Therapeutics' (AVTX) quarterly Cash from Operations came in at 17700000.0 in Q1 2026, down 87.16% YoY from 137882125.21 in Q1 2025, and down 23.88% on a QoQ basis from 14288000.0 in Q4 2025.
Avalo Therapeutics (AVTX) Cash from Operations (2014 - 2026) Analysis & Trends
Avalo Therapeutics (AVTX) has 13 years of Cash from Operations data on file, last reported at 17700000.0 in Q1 2026.
- Quarterly Cash from Operations fell 87.16% year-over-year to 17700000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 59743000.0 (down 14.21% YoY) and the FY2025 annual result came in at 51500000.0, down 4.98% from the prior year.
- Cash from Operations fell to 17700000.0 in Q1 2026, from 14288000.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 5726000.0 in Q3 2022 to a low of 17700000.0 in Q1 2026.
- A 5-year average of 10334529.41 and a median of 11343000.0 in 2025 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2022 — Cash from Operations soared 135.15% — and 2024, when it tumbled 443.89%.
- Tracing AVTX's Cash from Operations over 5 years: stood at 3940000.0 in 2022, then advanced by 29.8% to 2766000.0 in 2023, then plunged by 443.89% to 15044000.0 in 2024, then climbed by 5.03% to 14288000.0 in 2025, then fell by 23.88% to 17700000.0 in 2026.
- The last three Cash from Operations figures came in at 17700000.0 (Q1 2026), 14288000.0 (Q4 2025), and 16412000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -387.32 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 462.82 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 728.46 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 326.72 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Avalo Therapeutics | 854.16 Mn | 453.89 Mn | - | -20.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -20.00 Mn |
| Jun 30, 2026 | -20.00 Mn |
| Mar 31, 2026 | -17.70 Mn |
| Mar 31, 2026 | -17.70 Mn |
| Dec 31, 2025 | -14.29 Mn |
| Dec 31, 2025 | -14.29 Mn |
| Sep 30, 2025 | -16.41 Mn |
| Sep 30, 2025 | -16.41 Mn |
| Jun 30, 2025 | -11.34 Mn |
| Jun 30, 2025 | -11.34 Mn |
| Mar 31, 2025 | -9.46 Mn |
| Mar 31, 2025 | -9.46 Mn |
| Dec 31, 2024 | -15.04 Mn |
| Dec 31, 2024 | -15.04 Mn |
| Sep 30, 2024 | -11.53 Mn |
| Sep 30, 2024 | -11.53 Mn |
| Jun 30, 2024 | -16.28 Mn |
| Jun 30, 2024 | -16.28 Mn |
| Mar 31, 2024 | -6.20 Mn |
| Mar 31, 2024 | -6.20 Mn |